Q1 FY27 Results - Revenue up 18.6 percent, PAT up 16.6 percent YoY
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q1 FY27 revenue from operations rose 18.6 percent YoY to INR 1,038.1 million from INR 875.5 million. PAT grew 16.6 percent to INR 322.1 million from INR 276.2 million. EPS at INR 13.05 versus INR 11.19. Company has zero outstanding debt. Limited review report from BSR and Co LLP is clean with no qualifications. Separately, parent Novartis AG has agreed to sell its 70.68 percent stake to WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners, which will trigger a change in control and promoter classification.
Strong double-digit growth and zero debt point to healthy operations. Pending change of control is the key event for shareholders to track.